Stage IVB Prostate Cancer AJCC v8 — Expanded Access Programs
Overview
Right2Hope maintains a directory of 32 expanded access programs, clinical trials, and compassionate use pathways listed for Stage IVB Prostate Cancer AJCC v8. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with stage ivb prostate cancer ajcc v8 programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 12 programs are currently active or recruiting, with the remaining 20 in other lifecycle stages. Sponsors actively running programs in this area include Alliance for Clinical Trials in Oncology, Jonsson Comprehensive Cancer Center, Mayo Clinic, M.D. Anderson Cancer Center, Fred Hutchinson Cancer Center, and others.
By recruiting status
Snapshot of where every Stage IVB Prostate Cancer AJCC v8 program currently sits in its lifecycle.
- Active / Recruiting12
- Inactive20
Top sponsors
Organisations running the most Stage IVB Prostate Cancer AJCC v8 programs in the directory.
- Alliance for Clinical Trials in Oncology4 programs
- Jonsson Comprehensive Cancer Center4 programs
- Mayo Clinic4 programs
- M.D. Anderson Cancer Center3 programs
- Fred Hutchinson Cancer Center2 programs
- National Cancer Institute (NCI)2 programs
- SWOG Cancer Research Network2 programs
- University of Washington2 programs
- City of Hope Medical Center1 program
- ECOG-ACRIN Cancer Research Group1 program
Stage IVB Prostate Cancer AJCC v8 programs (32)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- The LUNAR Study: 177-Lutetium-PSMA Before Targeted Radiation for Treating Recurrent Prostate Cancer — Jonsson Comprehensive Cancer Center
- Study on Adding Rucaparib to Enzalutamide for Men with Metastatic Prostate Cancer Resistant to Testosterone-Deprivation Therapy — Alliance for Clinical Trials in Oncology
- Study on Abiraterone Acetate, Prednisone, and Apalutamide for Treating Patients with Untreated Metastatic Prostate Cancer — M.D. Anderson Cancer Center
- Study on Antiandrogen Therapy and Precision Radiation for Treating Recurrent, Metastatic Prostate Cancer — Jonsson Comprehensive Cancer Center
- Cell Therapy (STEAP1 CART) with Enzalutamide for Treating Advanced Prostate Cancer — Fred Hutchinson Cancer Center
- Study on the Effectiveness of Ra-223 in Patients with Prostate Cancer Selected by PSMA PET Scans — University of California, San Francisco
- Study on Enhanced 177Lu-PSMA-617 Treatment for Prostate Cancer with Low PSMA Expression — University of Washington
- Targeted Treatment for Metastatic Prostate Cancer: The PREDICT Trial — Alliance for Clinical Trials in Oncology
- Study on Different Dosing Schedules of Lutetium 177Lu PSMA RLT for Advanced Prostate Cancer — Alliance for Clinical Trials in Oncology
- Study on Adding Docetaxel to Usual Hormonal Therapy and Apalutamide for Metastatic Prostate Cancer — Alliance for Clinical Trials in Oncology
- Study on the Safety of Olaparib and Radium-223 for Men with Advanced Prostate Cancer with Bone Metastasis — National Cancer Institute (NCI)
- Study on Adding Carboplatin to Cabazitaxel for Treating Advanced Prostate Cancer — SWOG Cancer Research Network
- Study on Abemaciclib Before 177Lu-PSMA-617 for Treating Metastatic Castration-Resistant Prostate Cancer — Vadim S Koshkin
- Study on Apalutamide, Abiraterone Acetate, and Prednisone for Treating Metastatic Castration Resistant Prostate Cancer — M.D. Anderson Cancer Center
- Study on Cabozantinib and Atezolizumab for Treating Metastatic Castration-Resistant Prostate Cancer (The AtezoCab Trial) — University of Utah
- Study on CJNJ-67652000 and Prednisone for Treating Advanced Prostate Cancer with SPOP Gene Mutations — Mayo Clinic
- Study on Erdafitinib for Treating Castration-Resistant Prostate Cancer — M.D. Anderson Cancer Center
- Study on Using Targeted Radiation Therapy for Prostate Cancer with Rising PSA Levels After Surgery — Jonsson Comprehensive Cancer Center
- Study on FDG-PET-Guided Radiation Therapy for Treating Metastatic Hormone Sensitive Prostate Cancer (The PRTY Trial) — Northwestern University
- Study on Pertuzumab, Trastuzumab, Hyaluronidase-zzxf, and Enzalutamide for Treating Metastatic Castration-Resistant Prostate Cancer — Mayo Clinic
- Re-treatment with 177Lu-PSMA-617 for Treating Advanced Prostate Cancer Resistant to Hormone Therapy — Jonsson Comprehensive Cancer Center
- Study on Ruxolitinib and Enzalutamide for Treating Metastatic Castration-Resistant Prostate Cancer — University of Michigan Rogel Cancer Center
- Study on Adjusting 177Lu-PSMA-617 Treatment for Advanced Prostate Cancer — Mayo Clinic
- Study on Standard Therapy With or Without Surgery or Radiation for Metastatic Prostate Cancer — SWOG Cancer Research Network
- Study on Radiation Therapy Plus Hormone Treatments for Metastatic, Recurrent Hormone-Sensitive Prostate Cancer (DIVINE Trial) — Mayo Clinic
- Study on Using High Levels of Testosterone to Enhance Chemotherapy in Advanced Prostate Cancer (SPECTRA Study) — University of Washington
- Study on Talazoparib with Hormone Therapy and Abiraterone for Treating Prostate Cancer Sensitive to Hormone Therapy — City of Hope Medical Center
- Testing the Addition of Relugolix to Radiation Therapy for Advanced Prostate Cancer — NRG Oncology
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors — National Cancer Institute (NCI)
- Treating Prostate Cancer That Has Returned After Surgery with Apalutamide and Targeted Radiation Based on PET Imaging — ECOG-ACRIN Cancer Research Group
- Study on Vorinostat and 177Lu-PSMA-617 for Treating PSMA-Low Metastatic Castration-Resistant Prostate Cancer — Fred Hutchinson Cancer Center
- Study on ZEN-3694, Enzalutamide, and Pembrolizumab for Treating Metastatic Castration-Resistant Prostate Cancer — Rahul Aggarwal
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Stage IVB Prostate Cancer AJCC v8 to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.